A Pragmatic,Person-Centered View of Cannabis in the United States: Pursuing Care That Transcends Beliefs

National Academies of Sciences Engineering and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press; 2017.

Weaver MF Jarvis MAE Schnoll SH. Role of the primary care physician in problems of substance abuse. Arch Intern Med. 1999;159(9):913-924. doi:10.1001/archinte.159.9.913

Carlini BH Garrett SB Carter GT. Medicinal cannabis: A survey among health care providers in Washington State. Am J Hosp Palliat Care. 2017;34(1):85-91. doi:10.1177/1049909115604669

Zolotov Y Vulfsons S Zarhin D Sznitman S. Medical cannabis: An oxymoron? Physicians’ perceptions of medical cannabis. Int J Drug Policy. 2018;57:4-10. doi:10.1016/j.drugpo.2018.03.025

Philpot LM Ebbert JO Hurt RT. A survey of the attitudes, beliefs and knowledge about medical cannabis among primary care providers. BMC Fam Pract. 2019;20(1):17. doi:10.1186/s12875-019-0906-y

Braun IM Wright A Peteet J , et al. Medical oncologists’ beliefs, practices, and knowledge regarding marijuana used therapeutically: A nationally representative survey study. J Clin Oncol. 2018;36(19):1957-1962. doi:10.1200/JCO.2017.76.1221

McLennan A Kerba M Subnis U Campbell T Carlson LE. Health care provider preferences for, and barriers to, cannabis use in cancer care. Curr Oncol. 2020;27(2):199-205. doi:10.3747/co.27.5615

Blevins CE Rawat N Stein MD. Gaps in the substance use disorder treatment referral process: Provider perceptions. J Addict Med. 2018;12(4):273-277. doi:10.1097/ADM.0000000000000400

Boehnke KF Litinas E Worthing B Conine L Kruger DJ. Communication between healthcare providers and medical cannabis patients regarding referral and medication substitution. J Cannabis Res. 2021;3(1):2. doi:10.1186/s42238-021-00058-0

Ebbert JO Scharf EL Hurt RT. Medical cannabis. Mayo Clin Proc. 2018;93(12):1842-1847. doi:10.1016/j.mayocp.2018.09.005

McNeely J Kumar PC Rieckmann T , et al. Barriers and facilitators affecting the implementation of substance use screening in primary care clinics: a qualitative study of patients, providers, and staff. Addict Sci Clin Pract. 2018;13(1):8. doi:10.1186/s13722-018-0110-8

United States Pharmacopœial Convention. The Pharmacopoeia of the United States of America. Wells and Lilly for Charles Ewer; 1916.

Smith R. U. S. Marijuana legislation and the creation of a social problem. J Psychedelic Drugs. 1968;2(1):93-104. doi:10.1080/02791072.1968.10524403

Griffin OH Fritsch AL Woodward VH Mohn RS. Sifting through the hyperbole: one hundred years of marijuana coverage in The New York Times. Deviant Behav. 2013;34(10):767-781. doi:10.1080/01639625.2013.766548

Reid M. A qualitative review of cannabis stigmas at the twilight of prohibition. J Cannabis Res. 2020;2(1):46. doi:10.1186/s42238-020-00056-8

Sloman L . Reefer Madness : The History of Marijuana in America. St. Martin’s Griffin; 1998. Accessed October 18, 2021. http://archive.org/details/reefermadnesshis0000slom

Mootz FJI . Ethical cannabis lawyering in California. St Marys J Leg Malpract Ethics. 2018;9:2.

The Controlled Substances Act. United States Drug Enforcement Adminstration (DEA). Accessed April 5, 2023. https://www.dea.gov/drug-information/csa

Bachman JG Johnson LD O’Malley PM. Explaining recent increases in students’ marijuana use: impacts of perceived risks and disapproval, 1976 through 1996. Am J Public Health. 1998;88(6):887-892. doi:10.2105/AJPH.88.6.887

Van Green T . Americans Overwhelmingly Say Marijuana Should Be Legal for Recreational or Medical Use. Pew Research Center; 2021. Accessed February 15, 2022. https://www.pewresearch.org/fact-tank/2021/04/16/americans-overwhelmingly-say-marijuana-should-be-legal-for-recreational-or-medical-use/

Felson J Adamczyk A Thomas C. How and why have attitudes about cannabis legalization changed so much? Soc Sci Res. 2019;78:12-27. doi:10.1016/j.ssresearch.2018.12.011

Compton WM Han B Jones CM Blanco C Hughes A. Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys. Lancet Psychiatry. 2016;3(10):954-964. doi:10.1016/S2215-0366(16)30208-5

Carliner H Brown QL Sarvet AL Hasin DS. Cannabis use, attitudes, and legal status in the U.S.: a review. Prev Med. 2017;104:13-23. doi:10.1016/j.ypmed.2017.07.008

Pew Research Center. Race, Immigration, Same-Sex Marriage, Abortion, Global Warming, Gun Policy, Marijuana Legalization. Pew Research Center; 2020. Accessed February 15, 2022. https://www.pewresearch.org/politics/2018/03/01/4-race-immigration-same-sex-marriage-abortion-global-warming-gun-policy-marijuana-legalization/

National Conference of State Legislatures. State Medical Cannabis Laws; 2023. Accessed July 23, 2023. https://www.ncsl.org/health/state-medical-cannabis-laws

Kleiman M Caulkins JP Hawken A. Drugs and Drug Policy: What Everyone Needs to Know. Oxford University Press; 2011.

Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2021 national survey on drug use and health. Accessed July 20, 2023. https://www.samhsa.gov/data/sites/default/files/reports/rpt39443/2021NSDUHFFRRev010323.pdf

Substance Abuse and Mental Health Services Administration (SAMHSA) 2020 national survey of drug use and health (NSDUH) Annual National Report; 2021. Accessed February 15, 2022. https://www.samhsa.gov/data/report/2020-nsduh-annual-national-report

Hasin DS Shmulewitz D Sarvet AL. Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: a narrative review and new findings. Am J Drug Alcohol Abuse. 2019;45(6):623-643. doi:10.1080/00952990.2019.1569668

Davenport SS Caulkins JP. Evolution of the United States Marijuana market in the decade of liberalization before full legalization. J Drug Issues. 2016;46(4):411-427. doi:10.1177/0022042616659759

Kilmer B Caulkins J Kilborn M Priest M Warren K. Cannabis legalization and social equity: some opportunities, puzzles, and trade-offs. Boston Univ Law Rev. 2021;(101): 1003–1041.

Center for Behavioral Health Statistics and Quality. Racial/Ethnic Differences in Substance Use, Substance Use Disorders, and Substance Use Treatment Utilization among People Aged 12 or Older (2015-2019). Substance Abuse and Mental Health Services Administration; 2021. https:// www.samhsa.gov/data/

Philbin MM Mauro PM Greene ER Martins SS. State-level marijuana policies and marijuana use and marijuana use disorder among a nationally representative sample of adults in the United States, 2015-2017: Sexual identity and gender matter. Drug Alcohol Depend. 2019;204:107506. doi:10.1016/j.drugalcdep.2019.06.009

Barger BT Obedin-Maliver J Capriotti MR Lunn MR Flentje A. Characterization of substance use among underrepresented sexual and gender minority participants in the population research in identity and disparities for equality (PRIDE) study. Subst Abuse. 2021;42(1):104-115. doi:10.1080/08897077.2019.1702610

NIH RePORT. Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC). National Institutes of Health (NIH); 2021. Accessed October 16, 2021. https://report.nih.gov/funding/categorical-spending#/

National Academies of Sciences Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, et al. Challenges and Barriers in Conducting Cannabis Research. National Academies Press (US); 2017. Accessed October 16, 2021. https://www.ncbi.nlm.nih.gov/books/NBK425757/

Stith SS Vigil JM. Federal barriers to Cannabis research. Science. 2016;352(6290):1182. doi:10.1126/science.aaf7450

Cash MC Cunnane K Fan C Romero-Sandoval EA. Mapping cannabis potency in medical and recreational programs in the United States. PLOS ONE. 2020;15(3):e0230167. doi:10.1371/journal.pone.0230167

Carlini BH. Potency increase, product development and marijuana marketing in times of legalization. Addiction. 2017;112(12):2178-2179. doi:10.1111/add.13945

Matson TE Carrell DS Bobb JF , et al. Prevalence of medical cannabis use and associated health conditions documented in electronic health records among primary care patients in Washington State. JAMA Netw Open. 2021;4(5):e219375. doi:10.1001/jamanetworkopen.2021.9375

Lyon L. THC and CBD: is medical cannabis overhyped or under-prescribed? Brain. 2020;143(4):e34-e34. doi:10.1093/brain/awaa066

Gali K Narode R Young-Wolff KC Rubinstein ML Rutledge G Prochaska JJ. Online patient-provider cannabis consultations. Prev Med. 2020;132:105987. doi:10.1016/j.ypmed.2020.105987

Phillips KA Thrush PT Lal AK , et al. Marijuana in pediatric and adult congenital heart disease heart transplant listing: a survey of provider practices and attitudes. Pediatr Transplant. 2020;24(2):e13640. doi:10.1111/petr.13640

Sobesky M Gorgens K. Cannabis and adolescents: Exploring the substance misuse treatment provider experience in a climate of legalization. Int J Drug Policy. 2016;33:66-74. doi:10.1016/j.drugpo.2016.02.008

Holland CL Nkumsah MA Morrison P , et al. “Anything above marijuana takes priority”: obstetric providers’ attitudes and counseling strategies regarding perinatal marijuana use. Patient Educ Couns. 2016;99(9):1446-1451. doi:10.1016/j.pec.2016.06.003

Collen M. Prescribing cannabis for harm reduction. Harm Reduct J. 2012;9(1):1. doi:10.1186/1477-7517-9-1

Mikuriya TH. Cannabis as a substitute for alcohol: A harm-reduction approach. J Cannabis Ther. 2004;4(1):79-93. doi:10.1300/J175v04n01_04

Denham BE. Attitudes toward legalization of marijuana in the United States, 1986-2016: changes in determinants of public opinion. Int J Drug Policy. 2019;71:78-90. doi:10.1016/j.drugpo.2019.06.007

Brooks E Gundersen DC Flynn E Brooks-Russell A Bull S. The clinical implications of legalizing marijuana: are physician and non-physician providers prepared? Addict Behav. 2017;72:1-7. doi:10.1016/j.addbeh.2017.03.007

Cooke AC Knight KR Miaskowski C. Patients’ and clinicians’ perspectives of co-use of cannabis and opioids for chronic non-cancer pain management in primary care. Int J Drug Policy. 2019;63:23-28. doi:10.1016/j.drugpo.2018.09.002

Gray TR Eiden RD Leonard KE Connors GJ Shisler S Huestis MA. Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth. Clin Chem. 2010;56(9):1442-1450. doi:10.1373/clinchem.2010.147876

Gunn JKL Rosales CB Center KE , et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6(4):e009986. doi:10.1136/bmjopen-2015-009986

Hasin DS. US epidemiology of cannabis use and associated problems. Neuropsychopharmacology. 2018;43(1):195-212. doi:10.1038/npp.2017.198

Cerdá M Mauro C Hamilton A , et al. Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiatry. 2020;77(2):165. doi:10.1001/jamapsychiatry.2019.3254

Budney AJ Sofis MJ Borodovsky JT. An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use. Eur Arch Psychiatry Clin Neurosci. 2019;269(1):73-86. doi:10.1007/s00406-018-0976-1

Fergusson DM Boden JM Horwood LJ. Psychosocial sequelae of cannabis use and implications for policy: findings from the christchurch health and development study. Soc Psychiatry Psychiatr Epidemiol. 2015;50(9):1317-1326. doi:10.1007/s00127-015-1070-x

Pratt M Stevens A Thuku M , et al. Benefits and harms of medical cannabis: a scoping review of systematic reviews. Syst Rev. 2019;8(1):320. doi:10.1186/s13643-019-1243-x

López-Pelayo H Batalla A Balcells MM Colom J Gual A. Assessment of cannabis use disorders: a systematic review of screening and diagnostic instruments. Psychol Med. 2015;45(6):1121-1133. doi:10.1017/S0033291714002463

Bonn-Miller MO Heinz AJ Smith EV Bruno R Adamson S. Preliminary development of a brief cannabis use disorder screening tool: the cannabis use disorder identification test short-form. Cannabis Cannabinoid Res. 2016;1(1):252-261. doi:10.1089/can.2016.0022

Matson TE Lapham GT Bobb JF , et al. Validity of the single-item screen–cannabis (SIS-C) for cannabis use disorder screening in routine care. JAMA Netw Open. 2022;5(11):e2239772. doi:10.1001/jamanetworkopen.2022.39772

Roy-Byrne P Maynard C Bumgardner K , et al. Are medical marijuana users different from recreational users? The view from primary care. Am J Addict. 2015;24(7):599-606. doi:10.1111/ajad.12270

Woodruff SI Shillington AM. Sociodemographic and drug use severity differences between medical marijuana users and non-medical users visiting the emergency department. Am J Addict. 2016;25(5):385-391. doi:10.1111/ajad.12401

Wilson J Mills K Freeman TP Sunderland M Visontay R Marel C. Weeding out the truth: a systematic review and meta-analysis on the transition from cannabis use to opioid use and opioid use disorders, abuse or dependence. Addiction. 2022;117(2):284-298. doi:10.1111/add.15581

Coughlin LN Lin LA Bonar EE. An agenda for research to transform care for cannabis use disorder. Addict Behav. Published online June 12, 2023. doi:10.1016/j.addbeh.2023.107774

Barlow DH Nock MK. Why can’t we be more idiographic in our research? Perspect Psychol Sci. 2009;4(1):19-21. doi:10.1111/j.1745-6924.2009.01088.x

Fisher AJ. Toward a dynamic model of psychological assessment: implications for personalized care. J Consult Clin Psychol. 2015;83(4):825-836. doi:10.1037/ccp0000026

Haynes SN Mumma GH Pinson C. Idiographic assessment: conceptual and psychometric foundations of individualized behavioral assessment. Clin Psychol Rev. 2009;29(2):179-191. doi:10.1016/j.cpr.2008.12.003

Piccirillo ML Rodebaugh TL. Foundations of idiographic methods in psychology and applications for psychotherapy. Clin Psychol Rev. 2019;71:90-100. doi:10.1016/j.cpr.2019.01.002

Fisher AJ Medaglia JD Jeronimus BF. Lack of group-to-individual generalizability is a threat to human subjects research. Proc Natl Acad Sci. 2018;115(27):E6106-E6115. doi:10.1073/pnas.1711978115

McCormack B McCance TV. Development of a framework for person-centred nursing. J Adv Nurs. 2006;56(5):472-479. doi:10.1111/j.1365-2648.2006.04042.x

Substance Aubse and Mental Health Services Administration. Know the risks of marijuana. Accessed March 10, 2022. https://www.samhsa.gov/marijuana

Johnson EC Demontis D Thorgeirsson TE , et al. A large-scale genome-wide association study meta-analysis of cannabis use disorder. Lancet Psychiatry. 2020;7(12):1032-1045. doi:10.1016/S2215-0366(20)30339-4

Pinto JV Medeiros LS Santana da Rosa G , et al. The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: a systematic review with meta-analysis and meta-regression. Neurosci Biobehav Rev. 2019;101:78-84. doi:10.1016/j.neubiorev.2019.04.004

Liu Y Williamson V Setlow B Cottler LB Knackstedt LA. The importance of considering polysubstance use: lessons from cocaine research. Drug Alcohol Depend. 2018;192:16-28. doi:10.1016/j.drugalcdep.2018.07.025

Haynes SN O’Brien WH. Functional analysis in behavior therapy. Clin Psychol Rev. 1990;10(6):649-668. doi:10.1016/0272-7358(90)90074-K

Greenhalgh T Thorne S Malterud K. Time to challenge the spurious hierarchy of systematic over narrative reviews? Eur J Clin Invest. 2018;48(6):e12931. doi:10.1111/eci.12931

Center for Disease and Control. Marijuana and public health. Published May 1, 2023. Accessed August 12, 2023. https://www.cdc.gov/marijuana/index.htm

Shah S Schwenk ES Sondekoppam RV , et al. ASRA pain medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids. Reg Anesth Pain Med. 2023;48(3):97-117. doi:10.1136/rapm-2022-104013

Canada Health. Understanding the access to cannabis for medical purposes regulations. Published August 11, 2016. Accessed August 12, 2023. https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/understanding-new-access-to-cannabis-for-medical-purposes-regulations.html

SAMHSA - Substance Abuse and Mental Health Services Administration. SAMHSA - The substance abuse mental health services administration. Accessed July 20, 2023. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report

Shapiro B Coffa D McCance-Katz EF. A primary care approach to substance misuse. Am Fam Physician. 2013;88(2):113-121.

Calomarde-Gómez C Jiménez-Fernández B Balcells-Oliveró M Gual A López-Pelayo H. Motivational interviewing for cannabis use disorders: a systematic review and meta-analysis. Eur Addict Res. 2021;27(6):413-427. doi:10.1159/000515667

Pollak KI Back AL Tulsky JA. Disseminating effective clinician communication techniques: engaging clinicians to want to learn how to engage patients. Patient Educ Couns. 2017;100(10):1951-1954. doi:10.1016/j.pec.2017.05.015

Rollnick S Miller WR. What is motivational interviewing? Behav Cogn Psychother. 1995;23(4):325-334. doi:10.1017/S135246580001643X

Welcome to the Motivational Interviewing Website! | Motivational interviewing network of trainers (MINT). Accessed March 8, 2023. https://motivationalinterviewing.org/

Hargraves D White C Frederick R , et al. Implementing SBIRT (Screening, brief intervention and referral to treatment) in primary care: lessons learned from a multi-practice evaluation portfolio. Public Health Rev. 2017;38(1):31. doi:10.1186/s40985-017-0077-0